Invitation to presentation of Xbrane Biopharma’s Year-end report 2019 on February 28, 2020

Corporate Information

English

News

Presentation

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on February 28th, 2020, at 10.00 a.m. CET. Xbrane will publish the company’s Year-end report for 2019, on Friday February 28th, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the Year-end report for 2019, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 000
UK (Local): +44 (0) 844 571 88 92
UK (Toll free): 08 003 767 922
Sweden (Local): +46 (0) 850 692 180
Sweden (Toll free): 020 012 55 81
US (Local): +1 631 510 74 95
US (Toll free): +1 866 966 13 96

Confirmation Code: 78 85 179

Web link:
https://edge.media-server.com/mmc/p/awbt9ry7

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane’s headquarter is located in Solna outside of Stockholm and the company’s in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.